The type 1 insulin-like growth factor receptor (IGF-1R) and its downstream signaling
components have become increasingly recognized as having a driving role in the …

Importance of the field: Lung cancer is the leading cause of cancer-related mortality
worldwide. NSCLC accounts for> 80% of all lung cancers. The treatment of advanced fit …

The insulin-like growth factor (IGF) pathway is a complex pathway involving interactions
between membrane-bound receptors, ligands, binding proteins, downstream effectors, and …

Objectives The insulin-like growth factor (IGF) signaling pathway has been implicated in the
pathogenesis of numerous tumor types, including non-small cell lung cancer (NSCLC) …

The insulin-like growth factor (IGF) pathway is involved in the normal control of fetal
development, tissue growth, and metabolism. Two distinct ligands (insulin-like growth factor …

Lung cancer leads all other cancers in both incidence and mortality. Recent advances in
underlying molecular pathogenesis have validated a panel of protein tyrosine kinases as …

The IGF1R signaling pathway is a complex and tightly regulated network that is critical for
cell proliferation, growth, and survival. IGF1R is a potential therapeutic target for patients …

Phase III trials of the anti-insulin-like growth factor-1 receptor (IGF1R) antibody figitumumab
in non-small cell lung cancer (NSCLC) patients have been discontinued owing to lack of …

Abstract Figitumumab (CP-751,871) is a fully human immunoglobulin G2 monoclonal
antibody highly potent and specific against the insulin-like growth factor-1 receptor …

Purpose: This study aimed to identify molecular determinants of sensitivity of non–small cell
lung cancer (NSCLC) to anti–insulin-like growth factor receptor (IGF-IR) therapy …